WEBULL
WebtradeDownload

How Investors May Respond To Leidos Holdings (LDOS) Naval Health Contract Win

Simply Wall St · 1d ago
  • Leidos Holdings has been awarded a US$56 million contract by the Naval Health Research Center to deliver behavioral health research, operational assessments, and data-driven analyses over a 66-month term for U.S. armed services personnel.
  • The award reinforces Leidos Holdings' role in long-duration, research-heavy defense health work, which can support utilization of its clinical data, analytics, and program management capabilities across its broader government services portfolio.
  • The focus now turns to how this long-term Naval Health Research Center award might influence Leidos Holdings' broader investment narrative.

Scan beyond Leidos Holdings and evaluate other defense and government services contractors on our curated list of list of solid balance sheet and fundamentals (24 results) that could benefit from similar multi year contract flows.

Leidos Holdings Investment Narrative Recap

To own Leidos Holdings, you need to believe in a long runway of U.S. government work in defense, intelligence, and health, with the business steadily winning complex, multi year contracts where its technical depth matters more than price alone. The Naval Health Research Center award helps on that front, but at US$56 million over 66 months it is not a major near term swing factor against roughly US$17.6b of annual revenue. The more immediate focus stays on execution in higher margin digital and AI programs, while debt levels, pricing pressure, and any shift in federal priorities remain key risks.

The Naval Health Research Center contract sits neatly beside Leidos Holdings' broader push into higher value digital modernization, AI, and recurring service work across national security and health. Recent commentary around earnings has highlighted analyst expectations for revenue growth of roughly 5% a year and earnings growth around 4.7% a year. A long duration research engagement in defense health does not rewrite that outlook, but it does support the narrative of steady, technically complex workloads. The open question is how much of the wider bid pipeline converts into similar multi year programs.

Even so, there is a structural weak spot in the Leidos Holdings story that could matter far more than this contract win if ...

Read the full Leidos Holdings narrative to see the case behind these numbers.

Leidos Holdings is currently expected to grow revenue by 5.4% a year, with analysts modeling earnings today of about US$1.4b, rising to roughly US$1.6b by 2029. This implies an earnings increase of about US$200m and supports a forecast for 2029 revenue of around US$20.7b.

Leidos Holdings' forecasts place fair value at $156.60 compared with the $133.05 share price, an 18% premium to its current price that could narrow quickly.

NYSE:LDOS 1-Year Stock Price Chart
NYSE:LDOS 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate view on Leidos Holdings focuses on margin risk rather than contract wins. The most cautious analysts were modeling revenue of about US$20.3b and earnings stuck near US$1.4b by 2029. That assumes shrinking margins and little earnings growth. This Naval Health Research Center award could nudge those expectations, so consider it an opportunity to compare different narratives and evaluate which assumptions you find more convincing.

For a broader sense check on where sentiment sits, compare this view with 2 other fair value estimates for Leidos Holdings to see how other investors are pricing Leidos Holdings.

Decide For Yourself

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Ideas Beyond Leidos Holdings?

Once you have a view on Leidos Holdings, it can help to widen the lens and compare it with other companies that fit different risk, income, and valuation profiles using the Simply Wall St Screener.

  • If you want income to do more of the work for you, consider steady payers by reviewing 6 dividend fortresses that combine high yields with solid fundamentals.
  • For investors hunting for mispriced opportunities, scan through 49 high quality undervalued stocks that pair stronger balance sheets with attractive P/E and cash flow metrics.
  • If capital preservation sits higher on your list than outsize returns, focus on resilience first and filter for 83 resilient stocks with low risk scores that may offer a smoother ride through market swings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.